Dr. Youssef Daali
My Social Links

Dr. Youssef Daali

Head of Laboratory
Geneva University Hospital, Switzerland

Highest Degree
Ph.D. in Pharmacy from University of Geneva, Switzerland

Share this Profile

Area of Interest:

Pharmacology and Toxicology
100%
Pharmaceutical Sciences
62%
Clinical Pharmacokinetics
90%
Drug Delivery
75%
Toxicokinetics
55%

Research Publications in Numbers

Books
0
Chapters
0
Articles
0
Abstracts
0

Selected Publications

  1. Marsousi, N., Y. Daali, P. Fontana, J.L. Reny and V. Ancrenaz-Sirot et al., 2018. Impact of boosted antiretroviral therapy on the pharmacokinetics and efficacy of clopidogrel and prasugrel active metabolites. Clin. Pharmacokinet., pp: 1-8 10.1007/s40262-018-0637-6.
    CrossRef  |  
  2. Lloret-Linares, C., M. Bosilkovska, Y. Daali, M. Gex-Fabry and K. Heron et al., 2018. Phenotypic assessment of drug metabolic pathways and p-glycoprotein in patients treated with antidepressants in an ambulatory setting. J. Clin. Psychiatry, Vol. 79. 10.4088/JCP.16m11387.
    CrossRef  |  
  3. Choong, E., C.R.S. Uppugunduri, D. Marino, M. Kuntzinger and F. Doffey-Lazeyras et al., 2018. Therapeutic drug monitoring of busulfan for the management of pediatric patients: cross-validation of methods and long-term performance. Ther. Drug Monit., 40: 84-92.
    CrossRef  |  
  4. Uppugunduri, C.R.S., F. Storelli, V. Mlakar, P. Huezo-Diaz Curtis and A. Rezgui et al., 2017. The association of combined GSTM1 and CYP2C9 genotype status with the occurrence of hemorrhagic cystitis in pediatric patients receiving myeloablative conditioning regimen prior to allogeneic hematopoietic stem cell transplantation. Front. Pharmacol., Vol. 8. 10.3389/fphar.2017.00451.
    CrossRef  |  
  5. Storelli, F., A. Matthey, S. Lenglet, A. Thomas, J. Desmeules and Y. Daali, 2017. Impact of CYP2D6 functional allelic variations on phenoconversion and drug-drug interactions. Clin. Pharmacol. Ther. 10.1002/cpt.889.
    CrossRef  |  
  6. Osorio Lujan, S., W. Habre, Y. Daali, Z. Pan and P.W. Kronen, 2017. Plasma concentrations of transdermal fentanyl and buprenorphine in pigs (Sus scrofa domesticus). Vet. Anaesthesia Analgesia, 44: 665-675.
    CrossRef  |  
  7. Marsousi, N., J.A. Desmeules, S. Rudaz and Y. Daali, 2017. Prediction of drug-drug interactions using physiologically-based pharmacokinetic models of CYP450 modulators included in Simcyp software. Biopharm. Drug Dispos., 39: 3-17.
    CrossRef  |  
  8. Lloret-Linares, C., Y. Daali, S. Chevret, I. Nieto and F. Molière et al., 2017. Exploring venlafaxine pharmacokinetic variability with a phenotyping approach, a multicentric french-swiss study (MARVEL study). BMC Pharmacol. Toxicol., Vol. 18. 10.1186/s40360-017-0173-2.
    CrossRef  |  
  9. Lloret-Linares, C., V. Rollason, K.I. Lorenzini, C. Samer and Y. Daali et al., 2017. Screening for genotypic and phenotypic variations in CYP450 activity in patients with therapeutic problems in a psychiatric setting, a retrospective study. Pharmacol. Res., 118: 104-110.
    CrossRef  |  
  10. Darwich, A.S., K. Ogungbenro, A.A. Vinks, J.R. Powell and J.L. Reny et al., 2017. Why has model-informed precision dosing not yet become common clinical reality? lessons from the past and a roadmap for the future. Clin. Pharmacol. Ther., 101: 646-656.
    CrossRef  |  
  11. Cusin, F., L. Fernandes Azevedo, P. Bonnaventure, J. Desmeules, Y. Daali and C.M. Pastor, 2017. Hepatocyte concentrations of indocyanine green reflect transfer rates across membrane transporters. Basic Clin. Pharmacol. Toxicol., 120: 171-178.
    CrossRef  |  
  12. Spaggiari, D., Y. Daali and S. Rudaz, 2016. An extensive cocktail approach for rapid risk assessment of in vitro CYP450 direct reversible inhibition by xenobiotic exposure. Toxicol. Appl. Pharmacol., 302: 41-51.
    CrossRef  |  
  13. Seredenina, T., Z. Nayernia, S. Sorce, G.J. Maghzal and A. Filippova et al., 2016. Evaluation of NADPH oxidases as drug targets in a mouse model of familial amyotrophic lateral sclerosis. Free Radic. Biol. Med., 97: 95-108.
    CrossRef  |  
  14. Romand, S., D. Spaggiari, N. Marsousi, C. Samer, J. Desmeules, Y. Daali and S. Rudaz, 2016. Characterization of oxycodone in vitro metabolism by human cytochromes P450 and UDP- glucuronosyltransferases. J. Pharma. Biomed. Anal., 144: 129-137.
    CrossRef  |  
  15. Ralvenius, W.T., M.A. Acuña, D. Benke, A. Matthey and Y. Daali et al., 2016. The clobazam metabolite n-desmethyl clobazam Is an α2 preferring benzodiazepine with an improved therapeutic window for antihyperalgesia. Neuropharmacol., 109: 366-375.
    CrossRef  |  
  16. Marsousi, N., F. Doffey-Lazeyras, S. Rudaz, J.A. Desmeules and Y. Daali, 2016. Intestinal permeability and P-glycoprotein-mediated efflux transport of ticagrelor in Caco-2 monolayer cells. Fundam Clin. Pharmacol., 30: 577-584.
    CrossRef  |  
  17. Marsousi, N., C.F. Samer, P. Fontana, J.L. Reny, S. Rudaz, J.A. Desmeules and Y. Daali, 2016. Coadministration of ticagrelor and ritonavir: Toward prospective dose adjustment to maintain an optimal platelet inhibition using the PBPK approach. Clin. Pharmacol. Ther., 100: 295-304.
    CrossRef  |  
  18. Ing Lorenzini, K., Y. Daali, P. Fontana, J. Desmeules and C. Samer, 2016. Rivaroxaban-induced hemorrhage associated with ABCB1 genetic defect. Front Pharmacol., Vol. 7. 10.3389/fphar.2016.00494.
    CrossRef  |  
  19. Daouk, S., N. Chèvre, N. Vernaz, C. Widmer, Y. Daali and S. Fleury-Souverain 2016. Dynamics of active pharmaceutical ingredients loads in a Swiss university hospital wastewaters and prediction of the related environmental risk for the aquatic ecosystems. Sci. Total Environ., 547: 244-253.
    CrossRef  |  
  20. Brun, C., Y. Daali, C. Combescure, A. Zufferey and A.D. Michelson et al., 2016. Aspirin response: Differences in serum thromboxane B2 levels between clinical studies. Platelets, 27: 196-202.
    CrossRef  |  
  21. Bosilkovska, M., K.I. Lorenzini, C.R.S. Uppugunduri, J. Desmeules, Y. Daali and M. Escher, 2016. Severe vincristine-induced neuropathic pain in a CYP3A5 nonexpressor with reduced CYP3A4/5 activity: Case study. Clin. Ther., 38: 216-220.
    CrossRef  |  
  22. Bosilkovska, M., C. Samer, J. Déglon, A. Thomas, B. Walder, J. Desmeules and Y. Daali, 2016. Evaluation of mutual drug-drug interaction within geneva cocktail for cytochrome P450 phenotyping using innovative dried blood sampling method. Basic Clin. Pharmacol. Toxicol., 119: 284-290.
    CrossRef  |  
  23. Acosta-Martin, A.E., P. Antinori, C.R. Uppugunduri, Y. Daali and M. Ansari et al., 2016. Detection of busulfan adducts on proteins. Rapid Commun. Mass Spectrom., 10.1002/rcm.7730.
    CrossRef  |  
  24. Huttner, A., E. Von Dach, A. Renzoni, B.D. Huttner and M. Affaticati et al., 2015. Augmented renal clearance, low β-lactam concentrations and clinical outcomes in the critically ill: An observational prospective cohort study. Int. J. Antimicrob. Agents, 45: 385-392.
    CrossRef  |  
  25. Daouk, S., S. Fleury-Souverain and Y. Daali, 2015. Development of an LC-MS/MS method for the assessment of selected active pharmaceuticals and metabolites in wastewaters of a Swiss University Hospital. CHIMIA Int. J. Chem., 69: 684-689.
    CrossRef  |  
  26. Daouk, S., N. Chèvre, N. Vernaz, P. Bonnabry, P. Dayer, Y. Daali, S. Fleury-Souverain, 2015. Prioritization methodology for the monitoring of active pharmaceutical ingredients in hospital effluents. J. Environ. Manage., 160: 324-332.
    CrossRef  |  
  27. Besson, M., A. Matthey, Y. Daali, A. Poncet and P. Vuillemier et al., 2015. GABAergic modulation in central sensitization in humans: A randomized placebo-controlled pharmacokinetic-pharmacodynamic study comparing clobazam with clonazepam in healthy volunteers. Pain, 156: 397-404.
    CrossRef  |  
  28. Uppugunduri, C.R., M.A. Rezgui, P.H. Diaz, A.K. Tyagi and J. Rousseau et al., 2014. The association of cytochrome P450 genetic polymorphisms with sulfolane formation and the efficacy of a busulfan-based conditioning regimen in pediatric patients undergoing hematopoietic stem-cell transplantation. Pharmacogenomics J., 14: 263-2671.
    CrossRef  |  
  29. Spaggiari, D., L. Geiser, Y. Daali and S. Rudaz, 2014. Phenotyping of CYP450 in human liver microsomes using the cocktail approach. Anal. Bioanal. Chem., 406: 4875-4887.
    CrossRef  |  
  30. Marsousi, N., Y. Daali, S. Rudaz, L. Almond, H. Humphries, J. Desmeules, C.F. Samer, 2014. Prediction of metabolic interactions with oxycodone via CYP2D6 and CYP3A inhibition using a physiologically based pharmacokinetic model. CPT Pharma. Syst. Pharmacol., Vol. 3. 10.1038/psp.2014.49.
    CrossRef  |  
  31. Kloth, J.S., H.J. Klumpen, H. Yu, K. Eechoute and C.F. Samer et al., 2014. Predictive value of CYP3A and ABCB1 phenotyping probes for the pharmacokinetics of sunitinib: The ClearSun study. Clin. Pharmacokinet., 53: 261-269.
    CrossRef  |  
  32. Daali, Y., J.L. Reny, P. Fontana, 2014. Role of paraoxonase-1 in CYP2C19 loss-of-function carriers. Thromb. Res., Vol. 133 10.1016/j.thromres.2013.12.034.
    CrossRef  |  
  33. Bouatou, Y., C. Samer, K. Ing Lorenzini, Y. Daali and S. Daou et al., 2014. Therapeutic drug monitoring of voriconazole: A case report of multiple drug interactions in a patient with an increased CYP2C19 activity. AIDS Res. Ther., Vol. 11. 10.1186/1742-6405-11-25.
    CrossRef  |  
  34. Bosilkovska, M., M. Clément, P. Dayer, J. Desmeules, Y. Daali, 2014. Incorporation of flurbiprofen in a 4-drug cytochrome P450 phenotyping cocktail. Basic Clin. Pharmacol. Toxicol., 115: 465-466.
    CrossRef  |  
  35. Bosilkovska, M., J. Déglon, C. Samer, B. Walder, J. Desmeules, C. Staub, Y. Daali, 2014. Simultaneous LC-MS/MS quantification of P-glycoprotein and cytochrome P450 probe substrates and their metabolites in DBS and plasma. Bioanalysis, 6: 151-164.
    CrossRef  |  
  36. Bosilkovska, M., C.F. Samer, J. Déglon, M. Rebsamen, C. Staub, P. Dayer, B. Walder, J.A. Desmeules, Y. Daali, 2014. Geneva cocktail for cytochrome P450 and P-glycoprotein activity assessment using dried blood spot. Clin. Pharmacol. Ther., 96: 349-359.
    CrossRef  |  
  37. Schenkel, F., C. Csajka, E. Baglivo, M. Kondo-Oestreicher, P. Dayer, M. Gex-Fabry and Y. Daali, 2013. Intraocular penetration of penciclovir after oral administration of famciclovir: A population pharmacokinetic model. J. Antimicrob. Chemother., 68: 1635-1641.
    CrossRef  |  
  38. Samer, C.F., K.I. Lorenzini, V. Rollason, Y. Daali and J.A. Desmeules, 2013. Applications of CYP450 testing in the clinical setting. Mol. Diagn. Ther., 17: 165-184.
    CrossRef  |  
  39. Matthey, A., C. Cedraschi, V. Piguet, M. Besson and J. Chabert et al., 2013. Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: A randomized double-blind placebo-controlled trial. Pain Physician, 16: E553-E562.
    Direct Link  |  
  40. Khanicheh, E., Y. Qi, A. Xie, M. Mitterhuber and L. Xu et al., 2013. Molecular imaging reveals rapid reduction of endothelial activation in early atherosclerosis with apocynin independent of antioxidative properties. Arterioscler Thromb. Vasc. Biol., 33: 2187-2192.
    CrossRef  |  
  41. Gschwind, L., V. Rollason, Y. Daali, P. Bonnabry, P. Dayer and J.A. Desmeules, 2013. Role of P-glycoprotein in the uptake/efflux transport of oral vitamin K antagonists and rivaroxaban through the Caco-2 cell model. Basic Clin. Pharmacol. Toxicol., 113: 259-265.
    CrossRef  |  
  42. Ehret, G.B., Y. Daali, J. Chabert, M. Rebsamen and A. Wolff et al., 2013. Influence of CYP2D6 activity on pre-emptive analgesia by the N-methyl-D-aspartate antagonist dextromethorphan in a randomized controlled trial of acute pain. Pain Physician, 16: 45-56.
    Direct Link  |  
  43. Daali, Y., P. Millet, P. Dayer and C.M. Pastor, 2013. Evidence of drug-drug interactions through uptake and efflux transport systems in rat hepatocytes: Implications for cellular concentrations of competing drugs. Drug Metab. Dispos., 41: 1548-1556.
    CrossRef  |  
  44. Besson, M., Y. Daali, A. Di Lio, P. Dayer, H.U. Zeilhofer, J. Desmeules, 2013. Antihyperalgesic effect of the GABA(A) ligand clobazam in a neuropathic pain model in mice: A pharmacokinetic-pharmacodynamic study. Basic Clin. Pharmacol. Toxicol., 112: 192-197.
    CrossRef  |  
  45. Ancrenaz, V., J. Déglon, C. Samer, C. Staub, P. Dayer, Y. Daali, J. Desmeules, 2013. Pharmacokinetic interaction between prasugrel and ritonavir in healthy volunteers. Basic Clin. Pharmacol. Toxicol., 112: 132-137.
    CrossRef  |